Welcome to our dedicated page for REVIVA PHARMA HLDGS news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on REVIVA PHARMA HLDGS stock.
Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.